Immune checkpoint inhibitors and diabetes

被引：0
作者：
Campbell, Nicola [1 ]
Poole, Ruth [2 ]
机构：
[1] Poole Hosp NHS Fdn Trust, Med Oncol, Poole, Dorset, England
[2] Poole Hosp NHS Fdn Trust, Diabet & Endocrinol, Poole, Dorset, England
来源：
PRACTICAL DIABETES | 2020年 / 37卷 / 03期
关键词：
MECHANISMS; EFFICACY;
D O I：
10.1002/pdi.2276
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In the first in this new series of articles on diabetes and cancer, Dr Nicola Campbell and Dr Ruth Poole focus on diabetes and checkpoint inhibitors which are becoming the most frequently used immunotherapies in the treatment of cancer. The increased immune activity from this treatment can result in the development of type 1 diabetes, as discussed here.
引用
收藏
页码：96 / 100
页数：5
相关论文
共 25 条
  • [1] Immune checkpoint inhibitor-induced Type 1 diabetes: a systematic review and meta-analysis
    Akturk, H. K.
    Kahramangil, D.
    Sarwal, A.
    Hoffecker, L.
    Murad, M. H.
    Michels, A. W.
    [J]. DIABETIC MEDICINE, 2019, 36 (09) : 1075 - 1081
  • [2] [Anonymous], 2013, The management of diabetic ketoacidosis in adults
  • [3] [Anonymous], 2015, TYP 1 DIAB AD DIAGN
  • [4] The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice
    Ansari, MJI
    Salama, AD
    Chitnis, T
    Smith, RN
    Yagita, H
    Akiba, H
    Yamazaki, T
    Azuma, M
    Iwai, H
    Khoury, SJ
    Auchincloss, H
    Sayegh, MH
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (01) : 63 - 69
  • [5] Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens A Systematic Review and Meta-analysis
    Barroso-Sousa, Romualdo
    Barry, William T.
    Garrido-Castro, Ana C.
    Hodi, F. Stephen
    Min, Le
    Krop, Ian E.
    Tolaney, Sara M.
    [J]. JAMA ONCOLOGY, 2018, 4 (02) : 173 - 182
  • [6] Bedrose Sara, 2020, AACE Clin Case Rep, V6, pe40, DOI 10.4158/ACCR-2019-0234
  • [7] Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
    Das, Satya
    Johnson, Douglas B.
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01)
  • [8] Mechanisms of PDL-1 mediated regulation of autoimmune diabetes
    Guleria, Indira
    Bupp, Melanie Gubbels
    Dada, Shirine
    Fife, Brian
    Tang, Qizhi
    Ansari, Mohammed Javeed
    Trikudanathan, Subbulaxmi
    Vadivel, Nidyanandh
    Fiorina, Paolo
    Yagita, Hideo
    Azuma, Miyuki
    Atkinson, Mark
    Bluestone, Jeffrey A.
    Sayegh, Mohamed H.
    [J]. CLINICAL IMMUNOLOGY, 2007, 125 (01) : 16 - 25
  • [9] Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Haanen, J. B. A. G.
    Carbonnel, F.
    Robert, C.
    Kerr, K. M.
    Peters, S.
    Larkin, J.
    Jordan, K.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 : 119 - 142
  • [10] Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
    Hodi, F. Stephen
    O'Day, Steven J.
    McDermott, David F.
    Weber, Robert W.
    Sosman, Jeffrey A.
    Haanen, John B.
    Gonzalez, Rene
    Robert, Caroline
    Schadendorf, Dirk
    Hassel, Jessica C.
    Akerley, Wallace
    van den Eertwegh, Alfons J. M.
    Lutzky, Jose
    Lorigan, Paul
    Vaubel, Julia M.
    Linette, Gerald P.
    Hogg, David
    Ottensmeier, Christian H.
    Lebbe, Celeste
    Peschel, Christian
    Quirt, Ian
    Clark, Joseph I.
    Wolchok, Jedd D.
    Weber, Jeffrey S.
    Tian, Jason
    Yellin, Michael J.
    Nichol, Geoffrey M.
    Hoos, Axel
    Urba, Walter J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (08) : 711 - 723
123